StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) stock

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.76−0.13 (-0.94%)

Close on Nov 18, 2026Market cap $4.81BP/E –Yield 0.00%

Erasca net income

Net income is the profit left for shareholders after every expense, interest and tax.

Erasca's net income for the twelve months ending Jun 30, 2026 was -$287.22M. For fiscal 2025 it was -$124.55M. The highest annual figure on record is -$101.66M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$124.55M–
FY2024Dec 31, 2024-$161.65M–
FY2023Dec 31, 2023-$125.04M–
FY2022Dec 31, 2022-$242.81M–
FY2021Dec 31, 2021-$122.76M–
FY2020Dec 31, 2020-$101.66M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.08M–
Q1 FY2026Mar 31, 2026-$183.44M–
Q4 FY2025Dec 31, 2025-$29.09M–
Q3 FY2025Sep 30, 2025-$30.61M–
Q2 FY2025Jun 30, 2025-$33.88M–
Q1 FY2025Mar 31, 2025-$30.97M–
Q4 FY2024Dec 31, 2024-$32.23M–
Q3 FY2024Sep 30, 2024-$31.20M–
Q2 FY2024Jun 30, 2024-$63.20M–
Q1 FY2024Mar 31, 2024-$35.02M–
Q4 FY2023Dec 31, 2023-$29.70M–
Q3 FY2023Sep 30, 2023-$30.36M–
Q2 FY2023Jun 30, 2023-$31.78M–
Q1 FY2023Mar 31, 2023-$33.20M–
Q4 FY2022Dec 31, 2022-$135.25M–
Q3 FY2022Sep 30, 2022-$35.49M–
Q2 FY2022Jun 30, 2022-$35.61M–
Q1 FY2022Mar 31, 2022-$36.46M–
Q4 FY2021Dec 31, 2021-$30.46M–
Q3 FY2021Sep 30, 2021-$46.07M–
Q2 FY2021Jun 30, 2021-$28.21M–
Q1 FY2021Mar 31, 2021-$18.02M–
Q4 FY2020Dec 31, 2020-$61.90M–
Q3 FY2020Sep 30, 2020-$10.61M–
Q2 FY2020Jun 30, 2020-$5.49M–
Q1 FY2020Mar 31, 2020-$23.66M–

More Erasca figures

See a number that looks wrong?